[8-K] Grace Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (NASDAQ: GRCE) filed a Form 8-K on 23 June 2025 under Item 2.02 to furnish – not file – its financial results for the fiscal year ended 31 March 2025.

The filing itself contains no numerical data; instead, it attaches a press release (Exhibit 99.1) that presumably holds the detailed results. Management explicitly states that the furnished information is exempt from Section 18 liability and will not be incorporated into other SEC filings unless specifically referenced.

No additional items (e.g., acquisitions, capital raises, leadership changes) were disclosed. Consequently, investors must review Exhibit 99.1 to evaluate revenue, earnings, cash position, or guidance. Until those figures are consulted, the market impact of this disclosure remains indeterminate.

Insights

Financial Analyst

TL;DR: GRCE furnished FY-25 results via 8-K; actual numbers reside in Exhibit 99.1, leaving the filing itself information-light and neutral for now.

The company met its disclosure obligations by issuing an 8-K promptly after year-end, signalling transparency and regulatory compliance. However, because the Form 8-K omits any balance-sheet or P&L figures, investors cannot assess operational performance, liquidity, or outlook from this document alone. The information is furnished rather than filed, limiting potential liability and underscoring management’s intent to provide a rapid but preliminary update. From a portfolio perspective, the content is not immediately impactful; the critical valuation data sit in the accompanying press release, which must be consulted separately before drawing conclusions.

false0001444192DECommon Stock, par valueNASDAQ00014441922025-06-232025-06-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2025

GRACE THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

State of Delaware	001-35776	98-1359336
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

103 Carnegie Center Suite 300
Princeton, New Jersey		08540
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 609-322-1602

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		GRCE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.”

On June 23, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal year ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing or document.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit		Description
99.1		Press Release, dated June 23, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			GRACE THERAPEUTICS, INC.
Date:	June 23, 2025	By:	/s/ Prashant Kohli
			Prashant Kohli
			Chief Executive Officer

FAQ

Why did Grace Therapeutics (GRCE) file a Form 8-K on June 23 2025?

To furnish a press release (Exhibit 99.1) announcing its fiscal-year-ended March 31 2025 financial results under Item 2.02.

Does the 8-K include any revenue or earnings numbers for FY-25?

No. The filing itself contains no numerical results; all figures are expected to be in the attached press release.

Is the furnished information considered "filed" with the SEC?

No. Management states the information is furnished under Item 2.02 and is not subject to Section 18 liabilities unless later incorporated by reference.

What exhibit accompanies this 8-K filing?

Exhibit 99.1: a press release dated June 23 2025 detailing Grace Therapeutics’ FY-25 financial results.

Were any other material events, such as mergers or leadership changes, disclosed?

No additional items beyond the FY-25 results press release were reported in this 8-K.